AMENDMENT AGREEMENTAmendment Agreement • January 22nd, 2024 • Orgenesis Inc. • Pharmaceutical preparations
This Amendment Agreement (the “Amendment”), dated as of January 16, 2024, is by and among Orgenesis Inc., a Nevada corporation (the “Company”), and the holder constituting a majority-in-interest of the shares of Common Stock and Pre-Funded Warrants issued pursuant to that certain Securities Purchase Agreement dated as of November 8, 2023, by and among the Company and the purchaser identified on the signature pages thereto (the “Investor”) (the “November 2023 Purchase Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth for such terms in November 2023 Purchase Agreement.
